Internal Medicine, Endocrinology, Diabetes, & Metabolism · Rochester Hills, MI
NPI
1477560308
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
2970 Crooks Rd, Suite A
Rochester Hills, MI, 48309
Phone (248) 844-1873
Groups this clinician bills Medicare through
Medicare paid, 2024
$225K
2,852 services
Medicare patients, 2024
1,250
Average age 74
Drug cost, 2024
$8.5M
17,311 prescriptions
Company payments, 2025
$32K
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Abdul Al-Kassab was code 99214 (office e&m - established), 1,638 times for 1,034 patients. In total Abdul Al-Kassab billed 2,852 services in 13 codes, and Medicare paid $225K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,638 | 1,034 | $97.21 | $159K |
| 95251 Test - Miscellaneous | Office | 347 | 211 | $27.32 | $9,481 |
| 99232 Hospital E&M - Subsequent | Facility | 303 | 127 | $64.95 | $20K |
| 99231 Hospital E&M - Subsequent | Facility | 270 | 103 | $41.27 | $11K |
| 99204 Office E&M - New | Office | 105 | 105 | $125.95 | $13K |
| 99222 Hospital E&M - Initial | Facility | 80 | 75 | $105.34 | $8,427 |
| 82962 Clinical Chemistry | Office | 76 | 74 | $3.21 | $244 |
| 99215 Office E&M - Established | Office | 17 | 17 | $149.64 | $2,544 |
By year: 2022 $267K for 3,701 services; 2023 $255K for 3,292 services; 2024 $225K for 2,852 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 76 | 74 | $3.21 | $244 |
Medicare prescription drug claims, 2024
In 2024, the drug Abdul Al-Kassab prescribed most often to Medicare patients was Levothyroxine Sodium, with 2,032 prescriptions and refills. In total Abdul Al-Kassab wrote 17,311 Medicare prescriptions that cost $8.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 2,032 | 5,390 | 575 | $26K |
| Jardiance Empagliflozin | 856 | 2,098 | 255 | $1.2M |
| Metformin Hcl Er Metformin Hcl | 747 | 2,035 | 238 | $9,727 |
| Rosuvastatin Calcium Generic | 734 | 1,958 | 224 | $13K |
| Atorvastatin Calcium Generic | 705 | 1,953 | 217 | $9,346 |
| Ozempic Semaglutide | 688 | 1,326 | 175 | $1.2M |
| Synthroid Levothyroxine Sodium | 612 | 1,599 | 166 | $68K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 587 | 1,652 | 238 | $135K |
| Novolog Flexpen Insulin Aspart | 558 | 1,354 | 230 | $244K |
| Levoxyl Levothyroxine Sodium | 545 | 1,503 | 159 | $18K |
| Metformin Hcl Generic | 434 | 1,211 | 139 | $5,090 |
| Humalog Kwikpen U-100 Insulin Lispro | 374 | 949 | 146 | $195K |
| Farxiga Dapagliflozin Propanediol | 351 | 768 | 98 | $412K |
| Mounjaro Tirzepatide | 339 | 490 | 69 | $502K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 328 | 872 | 147 | $48K |
Brand drugs: 8,155 claims; generic drugs: 7,779 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Abdul Al-Kassab $32K ($32K in general payments such as food, travel and fees) from 30 companies. The largest payer was Novo Nordisk Inc with $28K.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 37 | $28K |
| Abbott Laboratories ABT | 13 | $2,877 |
| Chiesi USA, Inc. | 1 | $300 |
| Amgen Inc. AMGN | 6 | $112 |
| Intra-Sana Laboratories | 1 | $66.91 |
| Verity Pharmaceuticals Inc. | 3 | $65.42 |
| Corcept Therapeutics CORT | 3 | $59.61 |
| Abbvie Inc. ABBV | 3 | $54.15 |
| Amphastar Pharmaceuticals, Inc. AMPH | 2 | $46.7 |
| Dexcom, Inc. DXCM | 2 | $46.62 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.